Literature DB >> 7185768

Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.

A J Reyntigens, J J Heykants, R J Woestenborghs, Y G Gelders, T J Aerts.   

Abstract

Plasma haloperidol levels were assayed in 181 chronic schizophrenic inpatients, who were monthly injected intramuscularly with haloperidol decanoate. Steady state levels are reached after the third monthly injection and then remain constant, being associated with a remarkably stable control of the psychotic condition. Between two subsequent injections the haloperidol levels decrease gradually by about half their initial value. The haloperidol plasma levels strongly correlate with the injected doses of the decanoate form. For a single dose of 100 mg haloperidol decanoate monthly the minimal steady state value is about 4 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7185768     DOI: 10.1159/000468580

Source DB:  PubMed          Journal:  Int Pharmacopsychiatry        ISSN: 0020-8272


  12 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

Review 2.  Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

Authors:  S R Marder; J W Hubbard; T Van Putten; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 3.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

4.  A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.

Authors:  S J Dencker; I Giös; E Mårtensson; T Nordén; G Nyberg; R Persson; G Roman; O Stockman; K O Svärd
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 5.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.

Authors:  D H Wiles; R G McCreadie; A Whitehead
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 7.  Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.

Authors:  R Beresford; A Ward
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

Review 8.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 9.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

10.  Comparative bioavailability study of two haloperidol decanoate containing products.

Authors:  G van Weringh; B J Komen; R E Thieme; R T van der Hoeven; T Vos
Journal:  Pharm World Sci       Date:  1994-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.